These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9149841)

  • 1. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems.
    Summerton J; Stein D; Huang SB; Matthews P; Weller D; Partridge M
    Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):63-70. PubMed ID: 9149841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA.
    Stein D; Foster E; Huang SB; Weller D; Summerton J
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):151-7. PubMed ID: 9212905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple method for delivering morpholino antisense oligos into the cytoplasm of cells.
    Partridge M; Vincent A; Matthews P; Puma J; Stein D; Summerton J
    Antisense Nucleic Acid Drug Dev; 1996; 6(3):169-75. PubMed ID: 8915501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers.
    Ghosh C; Iversen PL
    Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):263-74. PubMed ID: 10984120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morpholino antisense oligomers: the case for an RNase H-independent structural type.
    Summerton J
    Biochim Biophys Acta; 1999 Dec; 1489(1):141-58. PubMed ID: 10807004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA.
    Taylor MF; Paulauskis JD; Weller DD; Kobzik L
    J Biol Chem; 1996 Jul; 271(29):17445-52. PubMed ID: 8663413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
    Gao WY; Han FS; Storm C; Egan W; Cheng YC
    Mol Pharmacol; 1992 Feb; 41(2):223-9. PubMed ID: 1371582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving efficient delivery of morpholino oligos in cultured cells.
    Morcos PA
    Genesis; 2001 Jul; 30(3):94-102. PubMed ID: 11477682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translation inhibition by phosphorothioate oligodeoxynucleotides in cell-free systems.
    Ghosh MK; Ghosh K; Cohen JS
    Antisense Res Dev; 1992; 2(2):111-8. PubMed ID: 1327332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides.
    Yao ZQ; Zhou YX; Wang AL; Bai XF; Yang WS
    J Viral Hepat; 1995; 2(2):85-9. PubMed ID: 7493302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of potent phosphorothioate antisense oligonucleotides directed to human interleukin 10 gene product and their evaluation of antisense activity in U937 cells.
    Arima H; Takahashi M; Aramaki Y; Sakamoto T; Yuda K; Akiyama K; Goto T; Tsuchiya S
    Pharm Res; 1999 Aug; 16(8):1163-71. PubMed ID: 10468015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorothioate-phosphodiester oligonucleotide co-polymers: assessment for antisense application.
    Ghosh MK; Ghosh K; Cohen JS
    Anticancer Drug Des; 1993 Feb; 8(1):15-32. PubMed ID: 8386513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of antisense DNA: comparison of activity of anti-rabbit beta-globin oligodeoxyribonucleoside phosphorothioates with computer predictions of mRNA folding.
    Jaroszewski JW; Syi JL; Ghosh M; Ghosh K; Cohen JS
    Antisense Res Dev; 1993; 3(4):339-48. PubMed ID: 8155975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
    Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
    Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides.
    Cazenave C; Stein CA; Loreau N; Thuong NT; Neckers LM; Subasinghe C; Hélène C; Cohen JS; Toulmé JJ
    Nucleic Acids Res; 1989 Jun; 17(11):4255-73. PubMed ID: 2472605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake.
    Schmajuk G; Sierakowska H; Kole R
    J Biol Chem; 1999 Jul; 274(31):21783-9. PubMed ID: 10419493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization.
    Yaida Y; Nowak TS
    Regul Pept; 1995 Oct; 59(2):193-9. PubMed ID: 8584754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morpholino antisense oligomers: design, preparation, and properties.
    Summerton J; Weller D
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):187-95. PubMed ID: 9212909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs.
    Sazani P; Kang SH; Maier MA; Wei C; Dillman J; Summerton J; Manoharan M; Kole R
    Nucleic Acids Res; 2001 Oct; 29(19):3965-74. PubMed ID: 11574678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of some properties of a phosphorodithioate oligodeoxyribonucleotide for antisense application.
    Ghosh MK; Ghosh K; Dahl O; Cohen JS
    Nucleic Acids Res; 1993 Dec; 21(24):5761-6. PubMed ID: 8284226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.